Ovarian cancer cell surface

The ovarian cancer cell surface represents the complex interface between the tumor cell and its microenvironment, characterized by a unique landscape of overexpressed proteins, glycoproteins, and glycolipids. It is not a single therapeutic target but rather a cellular compartment that houses numerous validated molecular targets, including Mucin 16 (MUC16/CA-125), Folate Receptor Alpha (FRα), and Mesothelin (Bast RC Jr, et al., 2005, Int J Gynecol Cancer; Ledermann JA, et al., 2015, Ann Oncol). These surface-exposed molecules are critical for maintaining the malignant phenotype, facilitating processes such as cell-cell adhesion, signal transduction, and immune evasion (Coleman RL, et al., 2019, Gynecol Oncol). In modern oncology, the cell surface is the primary site for the binding of monoclonal antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cells. Because the term encompasses a wide variety of distinct molecular entities with different biological roles and pharmacological profiles, it is classified as an incorrect target designation for structured drug discovery data, which requires the identification of a specific protein or gene product.

Other names

Ovarian tumor cell surfaceOvarian cancer cell membraneOvarian carcinoma cell surface

Not applicable. This term refers to a cellular location or compartment containing various distinct molecular targets rather than a single druggable entity.